A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Key Inclusion Criteria:

- Subjects (male and female) must be between the ages of 18 and 60 years at screening

- Subjects must have genotype 1 Chronic Hepatitis C

- Subjects must be treatment naïve

- Subjects must have laboratory values at screening within limits as specified by the
protocol

Key Exclusion Criteria:

- Evidence of cirrhosis

- Female subjects who are pregnant or nursing or male subjects with a female partner of
childbearing potential who is unwilling to adhere to the contraception requirements,
is pregnant or nursing, or planning to become pregnant during the study

- Any other cause of significant liver disease in addition to hepatitis C

- Human immunodeficiency virus -1 or -2

- Diagnosis of or suspected hepatocellular carcinoma

- History of organ transplant, with the exception of corneal transplants and skin
grafts